• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    2/9/23 11:27:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    SC 13G/A 1 tv01575-omnicellinc.htm SCHEDULE 13G/A omnicellinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Omnicell Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  68213N109

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  68213N109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    74,721

    7.  SOLE DISPOSITIVE POWER

    4,310,743

    8.  SHARED DISPOSITIVE POWER

    119,572

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,430,315

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.92%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Omnicell Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2625 Augustine Drive, Suite 301
    Santa Clara, CA 95054

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    68213N109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $OMCL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Omnicell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

    5/14/25 8:50:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell downgraded by BofA Securities with a new price target

    BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

    10/31/24 7:49:39 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by Barclays with a new price target

    Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

    8/2/24 7:36:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    3/18/25 4:13:27 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 0.28% to 403,523 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/17/25 5:27:57 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 332 shares, decreasing direct ownership by 0.28% to 117,126 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/17/25 5:27:11 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Director Parrish Mark W was granted 6,828 shares, increasing direct ownership by 12% to 65,255 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/25 4:12:37 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $OMCL
    SEC Filings

    View All

    Omnicell Announces Second Quarter 2025 Results

    Omnicell delivers strong second quarter financial results Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its second quarter ended June 30, 2025. "We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided gu

    7/31/25 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025

    Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, July 31, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. A

    7/14/25 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

    Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,

    5/22/25 8:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form 10-Q filed by Omnicell Inc.

    10-Q - OMNICELL, INC. (0000926326) (Filer)

    8/6/25 4:06:36 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OMNICELL, INC. (0000926326) (Filer)

    7/31/25 6:33:32 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form S-8 filed by Omnicell Inc.

    S-8 - OMNICELL, INC. (0000926326) (Filer)

    6/18/25 4:04:58 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    View All

    Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

    The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

    9/25/24 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

    FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

    4/22/24 4:05:00 PM ET
    $CLOV
    $OMCL
    Medical Specialities
    Health Care
    Computer Manufacturing
    Technology

    Omnicell Elects Eileen Voynick to Board of Directors

    Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

    1/11/24 4:00:00 PM ET
    $MDRX
    $OMCL
    $CDK
    EDP Services
    Technology
    Computer Manufacturing
    Retail: Computer Software & Peripheral Equipment

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    12/11/23 9:36:42 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    9/11/23 1:33:44 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    2/9/23 11:27:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Financials

    Live finance-specific insights

    View All

    Omnicell Announces Second Quarter 2025 Results

    Omnicell delivers strong second quarter financial results Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its second quarter ended June 30, 2025. "We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided gu

    7/31/25 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025

    Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, July 31, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. A

    7/14/25 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Announces First Quarter 2025 Results

    Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

    5/6/25 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology